Goldman Sachs
NXTC icon

Goldman Sachs’s NextCure NXTC Stock Holding History

Goldman Sachs’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,790
Closed -$138K – 5970
2023
Q1 		$138K Sell
7,790
-18,022
-70% -$347K ﹤0.01% 5402
2022
Q4 		$437K Sell
25,812
-2,216
-8% -$51K ﹤0.01% 4945
2022
Q3 		$925K Sell
28,028
-223
-0.8% -$11.4K ﹤0.01% 4569
2022
Q2 		$1.59M Sell
28,251
-2,840
-9% -$148K ﹤0.01% 4242
2022
Q1 		$1.81M Buy
31,091
+3,330
+12% +$208K ﹤0.01% 4340
2021
Q4 		$2M Buy
27,761
+19,439
+234% +$1.63M ﹤0.01% 4250
2021
Q3 		$673K Sell
8,322
-1,474
-15% -$129K ﹤0.01% 5015
2021
Q2 		$944K Sell
9,796
-8,121
-45% -$831K ﹤0.01% 4810
2021
Q1 		$2.15M Sell
17,917
-1,473
-8% -$213K ﹤0.01% 3907
2020
Q4 		$2.54M Buy
19,390
+7,982
+70% +$1.03M ﹤0.01% 3549
2020
Q3 		$1.21M Buy
11,408
+6,423
+129% +$790K ﹤0.01% 3946
2020
Q2 		$1.28M Buy
4,985
+42
+0.8% +$16K ﹤0.01% 3787
2020
Q1 		$2.2M Buy
4,943
+3,793
+330% +$2.03M ﹤0.01% 3234
2019
Q4 		$777K Buy
1,150
+562
+96% +$282K ﹤0.01% 4272
2019
Q3 		$218K Buy
+588
New +$191K ﹤0.01% 4796

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Goldman Sachs's NXTC Position: Q2 2023 in Review

Goldman Sachs sold out of NextCure (NXTC) in Q2 2023, closing a stake of 7,790 shares — an estimated $138K sold.

Goldman Sachs first reported a position in NXTC in Q3 2019 and held it in 15 quarters. The position peaked at $2.54M in Q4 2020. 43 funds tracked by Wall St. Rank hold NXTC as of Q2 2023.

  • Goldman Sachs reported no remaining NextCure position as of Q2 2023 after selling out during the quarter.
  • Goldman Sachs sold 7,790 NextCure shares in Q2 2023, an estimated $138K.
  • Goldman Sachs first reported a position in NextCure in Q3 2019 and held it in 15 quarters.
  • Goldman Sachs's NextCure position peaked at $2.54M in Q4 2020.
  • 43 funds tracked by Wall St. Rank held NextCure as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.